TR201905101T4 - Doku faktörü yolak inhibitörüne (TFPI) karşı monoklonal antikorlar. - Google Patents

Doku faktörü yolak inhibitörüne (TFPI) karşı monoklonal antikorlar. Download PDF

Info

Publication number
TR201905101T4
TR201905101T4 TR2019/05101T TR201905101T TR201905101T4 TR 201905101 T4 TR201905101 T4 TR 201905101T4 TR 2019/05101 T TR2019/05101 T TR 2019/05101T TR 201905101 T TR201905101 T TR 201905101T TR 201905101 T4 TR201905101 T4 TR 201905101T4
Authority
TR
Turkey
Prior art keywords
tfpi
monoclonal antibodies
tissue factor
pathway inhibitor
factor pathway
Prior art date
Application number
TR2019/05101T
Other languages
English (en)
Inventor
Wang Zhuozhi
Murphy John
Marquardt Tobias
Moosmayer Dieter
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46932389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201905101(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of TR201905101T4 publication Critical patent/TR201905101T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

İnsan doku faktörü yolak inhibitörünün (TFPI) spesifik epitoplarına bağlanan izole monoklonal antikorlar ve bunları kodlayan izole nükleik asit molekülleri sağlanır. Aynı zamanda anti-TFPI monoklonal antikorları içeren farmasötik bileşimler ve koagülasyondaki yetersizlikler ve kusurların antikorlar uygulanarak tedavi edildiği yöntemler sağlanır.
TR2019/05101T 2011-04-01 2012-03-30 Doku faktörü yolak inhibitörüne (TFPI) karşı monoklonal antikorlar. TR201905101T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161471101P 2011-04-01 2011-04-01

Publications (1)

Publication Number Publication Date
TR201905101T4 true TR201905101T4 (tr) 2019-05-21

Family

ID=46932389

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/05101T TR201905101T4 (tr) 2011-04-01 2012-03-30 Doku faktörü yolak inhibitörüne (TFPI) karşı monoklonal antikorlar.

Country Status (37)

Country Link
US (5) US20140294832A1 (tr)
EP (1) EP2694544B1 (tr)
JP (4) JP6170903B2 (tr)
KR (2) KR20190079698A (tr)
CN (2) CN107090046A (tr)
AU (3) AU2012236296A1 (tr)
BR (1) BR112013025376A2 (tr)
CA (2) CA3068997A1 (tr)
CL (1) CL2013002811A1 (tr)
CO (1) CO6890074A2 (tr)
CR (1) CR20130499A (tr)
CU (1) CU20130128A7 (tr)
CY (1) CY1121538T1 (tr)
DK (1) DK2694544T3 (tr)
DO (1) DOP2013000218A (tr)
EA (2) EA201991704A3 (tr)
EC (1) ECSP13012913A (tr)
ES (1) ES2722824T3 (tr)
GT (1) GT201300229A (tr)
HK (1) HK1243426A1 (tr)
HR (1) HRP20190467T1 (tr)
HU (1) HUE042706T2 (tr)
IL (4) IL228633B (tr)
LT (1) LT2694544T (tr)
MX (1) MX2013011218A (tr)
MY (2) MY190951A (tr)
PE (1) PE20141149A1 (tr)
PH (4) PH12013502039B1 (tr)
PL (1) PL2694544T3 (tr)
PT (1) PT2694544T (tr)
RS (1) RS58633B1 (tr)
SG (2) SG10201602606UA (tr)
SI (1) SI2694544T1 (tr)
TR (1) TR201905101T4 (tr)
UA (1) UA113623C2 (tr)
WO (1) WO2012135671A2 (tr)
ZA (1) ZA201308169B (tr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2747721C (en) 2008-12-19 2021-07-20 Baxter International Inc. Tfpi inhibitors and methods of use
CN102325795B (zh) † 2008-12-22 2015-03-25 诺沃—诺迪斯克有限公司 针对组织因子途径抑制剂的抗体
RS59830B1 (sr) 2010-03-01 2020-02-28 Bayer Healthcare Llc Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
EP2547355B1 (en) 2010-03-19 2017-01-11 Baxalta GmbH Tfpi inhibitors and methods of use
CN107090046A (zh) * 2011-04-01 2017-08-25 拜尔健康护理有限责任公司 针对组织因子途径抑制物(tfpi)的单克隆抗体
EP2827883B1 (en) * 2012-03-21 2019-05-08 Baxalta GmbH Tfpi inhibitors and methods of use
SG11201406129QA (en) * 2012-03-30 2014-10-30 Bayer Healthcare Llc Protease-regulated antibodies
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
ES2926773T3 (es) * 2013-03-15 2022-10-28 Novo Nordisk As Anticuerpos capaces de unirse específicamente a dos epítopos en el inhibidor de la ruta del factor tisular
US20160009818A1 (en) 2013-03-15 2016-01-14 Bayer Healthcare Llc Anti-TFPI Antibody Variants with Differential Binding Across pH Range For Improved Pharmacokinetics
JP6584397B2 (ja) * 2013-07-19 2019-10-02 ノヴォ ノルディスク アー／エス 凝血促進活性を誘発することができる組織因子経路インヒビターのｎ末端部分を認識する抗体
CN106687482B (zh) * 2014-09-17 2022-01-25 诺和诺德股份有限公司 能够结合组织因子途径抑制剂(1-161)上的两个表位的抗体
EP4279128A3 (en) 2015-02-25 2024-02-28 Mogam Institute for Biomedical Research Novel antibody binding to tfpi and composition comprising the same
IL302353A (en) * 2015-08-19 2023-06-01 Pfizer TFPI inhibitory antibodies and their uses
CN112424593A (zh) * 2018-07-25 2021-02-26 索尼公司 凝血系统分析装置
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06153985A (ja) * 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
CN102325795B (zh) * 2008-12-22 2015-03-25 诺沃—诺迪斯克有限公司 针对组织因子途径抑制剂的抗体
RS59830B1 (sr) * 2010-03-01 2020-02-28 Bayer Healthcare Llc Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
CN107090046A (zh) * 2011-04-01 2017-08-25 拜尔健康护理有限责任公司 针对组织因子途径抑制物(tfpi)的单克隆抗体
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations

Also Published As

Publication number Publication date
IL274686A (en) 2020-06-30
BR112013025376A2 (pt) 2017-07-25
KR20140019428A (ko) 2014-02-14
GT201300229A (es) 2014-11-13
PH12013502039A1 (en) 2013-12-16
PL2694544T3 (pl) 2019-07-31
RS58633B1 (sr) 2019-05-31
MY165499A (en) 2018-03-27
EP2694544A2 (en) 2014-02-12
JP2018172411A (ja) 2018-11-08
IL228633B (en) 2018-03-29
AU2012236296A1 (en) 2013-10-24
CY1121538T1 (el) 2020-05-29
JP2017113019A (ja) 2017-06-29
PH12019500441A1 (en) 2020-10-12
NZ615969A (en) 2016-01-29
CR20130499A (es) 2013-10-24
EA201301107A1 (ru) 2014-11-28
WO2012135671A3 (en) 2012-12-13
WO2012135671A2 (en) 2012-10-04
US20190194353A1 (en) 2019-06-27
CA2831907A1 (en) 2012-10-04
JP6363747B2 (ja) 2018-07-25
HRP20190467T1 (hr) 2019-05-03
ZA201308169B (en) 2016-03-30
EP2694544B1 (en) 2019-01-23
IL283829A (en) 2021-07-29
MX2013011218A (es) 2013-10-17
CN107090046A (zh) 2017-08-25
KR101995302B1 (ko) 2019-07-02
IL257145A (en) 2018-03-29
JP6170903B2 (ja) 2017-07-26
SG193594A1 (en) 2013-10-30
EA201991704A2 (ru) 2020-03-31
KR20190079698A (ko) 2019-07-05
SG10201602606UA (en) 2016-04-28
CN103797030A (zh) 2014-05-14
CA2831907C (en) 2020-03-24
PE20141149A1 (es) 2014-08-28
PH12013502039B1 (en) 2013-12-16
DOP2013000218A (es) 2013-11-15
DK2694544T3 (en) 2019-04-15
HK1243426A1 (zh) 2018-07-13
JP2021019619A (ja) 2021-02-18
HUE042706T2 (hu) 2019-07-29
JP2014511685A (ja) 2014-05-19
ES2722824T3 (es) 2019-08-19
AU2019201814A1 (en) 2019-04-04
CA3068997A1 (en) 2012-10-04
IL228633A0 (en) 2013-12-31
EA034214B1 (ru) 2020-01-17
EP2694544A4 (en) 2015-03-25
EA201991704A3 (ru) 2020-06-30
US20220041752A1 (en) 2022-02-10
PH12019500439A1 (en) 2020-10-12
SI2694544T1 (sl) 2019-06-28
LT2694544T (lt) 2019-04-25
US20140294832A1 (en) 2014-10-02
UA113623C2 (uk) 2017-02-27
US20170107298A1 (en) 2017-04-20
CL2013002811A1 (es) 2014-02-28
PT2694544T (pt) 2019-04-02
CN103797030B (zh) 2017-05-31
US20180194857A1 (en) 2018-07-12
IL274686B (en) 2021-09-30
MY190951A (en) 2022-05-24
PH12019500440A1 (en) 2020-10-12
CU20130128A7 (es) 2014-03-26
ECSP13012913A (es) 2014-02-28
CO6890074A2 (es) 2014-03-10
AU2017203105A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
PH12019500439A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
EA201291034A1 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ B-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201492101A1 (ru) Антитела против fcrn
EA201791186A1 (ru) Антитела к cd38
EA201400579A1 (ru) Антитела к il-36r
UA109278C2 (uk) Лікарські засоби, які індукують апоптоз, для лікування раку і імунних і аутоімунних захворювань
UA107706C2 (uk) Апоптоз-індукуючий засіб для лікування раку й імунних і аутоімунних захворювань
EA201491011A1 (ru) Способы лечения с помощью ингибитора гамма-интерферона
EA201692166A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
GB201109238D0 (en) Antibodies
EA201390117A1 (ru) Композиция антител к vegfr-3